Calliditas Therapeutics, Inc. - רווח למניה ב-12 החודשים האחרונים CALT

סמלים רשמיים של חברת Calliditas Therapeutics, Inc. (CALT)

Scaling orphan drug sales in the US has created powerful operating leverage for Calliditas Therapeutics (CALT), reducing unit costs. This rolling year-over-year EPS chart visualizes this trend, where the 39.30 mark indicates the current level of profit dynamics. The foundation for growth is based on the promotion of Tarpeyo as the gold standard for IgA nephropathy therapy and streamlined rare drug logistics that eliminate product shortages.

CALT: רווח נקי למניה (EPS TTM) Calliditas 11.02.2024 - 20.02.2024

Calliditas Therapeutics AB - פילוחים אנליטיים ומדדי מפתח (CALT)

- מחיר שוק ויעדי מחיר של אנליסטים:
הערכת שווי פונדמנטלית של החברה:CALT - Calliditas
מוצר עיקרי של calliditas.se

Assessing the operational resilience of an asset begins with an analysis of profit generation rates. For Calliditas Therapeutics (CALT), which is developing a unique therapy system for IgA nephropathy, the key factor is the monetization of its niche leadership. The YoY TTM earnings per share trend reflects the percentage change in net income per share over the year compared to the previous period. A positive trend confirms the effective integration of the drug Tarpeyo into treatment protocols. Steady growth in this indicator signals the scaling of the business.